摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氧代-4-甲基戊腈 | 29509-06-6

中文名称
3-氧代-4-甲基戊腈
中文别名
4-甲基-3-氧代戊腈
英文名称
4-methyl-3-oxopentanonitrile
英文别名
4-methyl-3-oxopentanenitrile
3-氧代-4-甲基戊腈化学式
CAS
29509-06-6
化学式
C6H9NO
mdl
MFCD05664144
分子量
111.144
InChiKey
VKZGTORDNRVMIN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    62-65 °C
  • 沸点:
    102-104 °C
  • 密度:
    0.938±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    8
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.666
  • 拓扑面积:
    40.9
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险等级:
    6.1
  • 包装等级:
    III
  • 危险类别:
    6.1
  • 危险性防范说明:
    P261,P280,P301+P310,P311
  • 危险品运输编号:
    2810
  • 危险性描述:
    H301,H311,H331
  • 储存条件:
    2-8°C

SDS

SDS:b3068b6eee76beecedfb65429e88d49a
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Methyl-3-oxopentanenitrile
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Methyl-3-oxopentanenitrile
CAS number: 29509-06-6

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H9NO
Molecular weight: 111.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Synthesis of Certain Hydroxycarboxylic Acids Related to Isocitric Acid1
    摘要:
    DOI:
    10.1021/jo01100a020
  • 作为产物:
    描述:
    异丁酸乙酯正丁基锂盐酸 作用下, 以 正己烷 为溶剂, 反应 3.0h, 生成 3-氧代-4-甲基戊腈
    参考文献:
    名称:
    [EN] QUINAZOLINE DERIVATIVES
    [FR] DERIVES DE QUINAZOLINE
    摘要:
    这项发明涉及式(I)的喹唑啉衍生物或其药用盐、溶剂化合物或前药,其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个在描述中已定义的含义中具有任何含义;它们的制备方法,含有它们的药物组合物以及它们在制造用于治疗细胞增殖紊乱或与血管生成和/或血管通透性相关的疾病状态的药物的用途。
    公开号:
    WO2006040520A1
点击查看最新优质反应信息

文献信息

  • Substrate Evaluation of<i>Rhodococcus erythropolis</i>SET1, a Nitrile Hydrolysing Bacterium, Demonstrating Dual Activity Strongly Dependent on Nitrile Sub-Structure
    作者:Tracey M. Coady、Lee V. Coffey、Catherine O'Reilly、Claire M. Lennon
    DOI:10.1002/ejoc.201403201
    日期:2015.2
    Rhodococcus erythropolis SET1, a novel nitrile hydrolysing bacterial isolate, has been undertaken with 34 nitriles, 33 chiral and 1 prochiral. These substrates consist primarily of β-hydroxy nitriles with varying alkyl and aryl groups at the β position and containing in several compounds different substituents α to the nitrile. In the case of β-hydroxy nitriles without substitution at the α position
    红球菌 SET1 是一种新型腈水解细菌分离株,已使用 34 种腈、33 种手性和 1 种前手性进行了评估。这些底物主要由 β-羟基腈组成,在 β 位具有不同的烷基和芳基,并且在几种化合物中含有与腈不同的 α 取代基。在 α 位没有取代的 β-羟基腈的情况下,由于分离物的腈水解酶活性,酸是获得的主要产物,以及生物转化后回收的腈。出乎意料的是,当 β-羟基腈在该位置具有乙烯基时,发现酰胺是主要的水解产物。为了进一步探索这种行为,评估了在 α 位置包含吸电子基团的其他相关底物,在 SET1 存在下的生物转化过程中也观察到了酰胺。因此,这种新的分离物也证明了对似乎是底物依赖性的腈类的 NHase 活性。
  • [EN] NEW ARYL-QUINOLINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'ARYLQUINOLÉINE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2013064465A1
    公开(公告)日:2013-05-10
    The invention provides novel compounds having the general formula (I), wherein R1, R2, R3, R4 R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds.
    本发明提供了具有通用公式(I)的新颖化合物,其中R1、R2、R3、R4、R5、R6和n如本文所述,包括这些化合物的组合物以及使用这些化合物的方法。
  • NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF
    申请人:Frost Lisa M.
    公开号:US20090281062A1
    公开(公告)日:2009-11-12
    The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.
    本发明涉及亚硝基衍生物,包括在生理条件下捐赠亚硝基(HNO)的羟基亚硝基化合物的羧酸和磷酸酯。发明中的化合物和组合物可用于治疗和/或预防对亚硝基疗法有响应的疾病或病症的发作和/或发展,包括心力衰竭、缺血/再灌注损伤和癌症。
  • INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
    申请人:Dumas Jacques
    公开号:US20120046290A1
    公开(公告)日:2012-02-23
    This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
    本发明涉及一组芳香脲在治疗细胞因子介导的疾病(除癌症外)和蛋白水解酶介导的疾病(除癌症外)中的用途,以及用于此类治疗的药物组合物。
  • QUINOLINE DERIVATIVES
    申请人:Jung Frederic Henri
    公开号:US20090076075A1
    公开(公告)日:2009-03-19
    The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X 1 , p, R 1 , q, R 2 , R 3 , R 4 , R 5 Ring A, r and R 6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    这项发明涉及公式I的喹啉衍生物或其药用盐,其中X 1 ,p,R 1 ,q,R 2 ,R 3 ,R 4 ,R 5 ,环A,r和R 6 中的每一个具有在描述中定义的任何含义;它们的制备方法,含有它们的药物组合物以及它们在制造用于治疗细胞增殖紊乱的药物的药物中的使用。
查看更多